eligibility_summary
Adults (≥18) with untreated DEL/DHL DLBCL per WHO (DEL by IHC or HGBL with MYC+BCL2/BCL6 rearrangements), measurable disease, ECOG ≤2, life ≥6 mo, adequate marrow and organ function (counts, liver enzymes, CrCl ≥30, aPTT ≤1.5×ULN, LVEF >40%). HIV on effective ART with undetectable viral load and CD4 ≥250 allowed. Exclude: recent conflicting tx/immunosuppression, CNS involvement, severe allergy, significant effusions, pregnancy, active liver dz/TB, recent severe infection or surgery, uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study in previously untreated high‑risk DLBCL (double‑expressor and double/triple‑hit). Interventions: Loncastuximab tesirine (anti‑CD19 antibody–drug conjugate, delivers tesirine, a pyrrolobenzodiazepine dimer causing DNA cross‑links) plus rituximab (chimeric anti‑CD20 monoclonal antibody, B‑cell depletion via ADCC/CDC/apoptosis), followed by DA‑EPOCH‑R: etoposide (podophyllotoxin derivative, topoisomerase II poison), doxorubicin (anthracycline, intercalator/topoisomerase II inhibition/ROS), vincristine (vinca alkaloid, microtubule depolymerization), cyclophosphamide (alkylating agent, DNA cross‑links), and prednisone (corticosteroid, glucocorticoid‑mediated lympholysis). Targets/pathways: malignant B cells expressing CD19/CD20, DNA replication/repair (topo II), DNA cross‑linking/alkylation, microtubule dynamics, glucocorticoid signaling, immune effector killing of B cells.